Ernst & Young has delayed in filing its evidence in a lawsuit by Sydney-based investment firm London City Equities over its auditing of collapsed soda ash maker Penrice after hiring Holding Redlich to replace Allens just a few months before a mediation deadline.
Crown Resorts will fight to strike out allegations in a class action that the casino operator was liable for “oppressive conduct” under the Corporations Act, saying there was no legal basis for making the claims and no articulation by the class as to how the company engaged in the conduct.
Westpac has argued that ASIC should flesh out its case accusing the banking giant of insider trading before the $16 billion privatisation of electricity provider Ausgrid, saying the regulator has not explained the nature of the alleged inside information.
The cash-strapped litigation funder that initially agreed to bankroll a class action against Westpac over life insurance premiums will not earn a cent in commission under a proposed $30 million settlement.
Fossil fuel giant Shell Australia has partially won a challenge to a tax office decision denying deductions claimed over an acquisition the increased the company’s stake in Woodside Energy’s Browse Basin gas exploration joint venture project.
Several banks and executives facing criminal cartel charges over a $2.5 billion ANZ share placement have won access to interview notes taken by whistleblower JP Morgan prior to it being granted immunity, which the banks say will prove inconsistencies in the prosecution’s case.
Lawyers welcomed the government’s “overdue” announcement of a so-called patent box that will slash the tax rate on income derived from patented drug and biotech inventions developed in Australia, but called on the government to apply the regime to other sectors.
A Federal Court judge has ordered that a referee consider how junior barristers were used in assessing the legal costs in an insurance class action against Westpac which the bank has agreed to pay up to $30 million to settle.
Westpac has agreed to pay up to $30 million to settle a long-running class action over allegedly excessive insurance premiums which included a trip to the High Court that resulted in common fund orders being struck down in the early stages of class actions.
The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only “of the most marginal relevance”.